# Ranibizumab Versus Aflibercept for CRVO in Young Patients.

> **NCT05282420** · PHASE4 · UNKNOWN · sponsor: **South Valley University** · enrollment: 40 (estimated)

## Conditions studied

- Non-Ischemic Central Retinal Vein Occlusion With Macular Edema

## Interventions

- **PROCEDURE:** intravitreal injection of Ranibizumab
- **PROCEDURE:** intravitreal injection of Aflipercept
- **DRUG:** Ranibizumab
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT05282420
- **Lead sponsor:** South Valley University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282420, "Ranibizumab Versus Aflibercept for CRVO in Young Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05282420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*